Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

U.S. stocks open with little chane as investors anxiously await more news on Trump's tariff plans, Nvidia's earnings and ...

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

During the Consumer Analyst Group of New York (CAGNY) conference that took place Feb. 18-21, Food Business News had the opportunity to discuss the topic with Sean Connolly, president and chief ...

Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.